@nickhaining
We are excited to announce our $325 million #SeriesC financing. This new investment will enable ArsenalBio's ongoing development efforts and scale our manufacturing capabilities to develop T-cell medicines. We thank the new investors along with our existing investors for their support in helping us to achieve our goal to defeat cancer. #celltherapy #patientsfirst
arsenalbio.com/2024/09/04/ars…View quoted post on X
www.businesswire.com ArsenalBio Announces Presentation of Six Abstracts at AACR Annual Meeting Highlighting Programmable... ArsenalBio to share preclinical data at AACR on the use of integrated circuit T cells for the development of cell therapies for solid tumor cancers. We congratulate @EJohnWherry, of @PennMedicine on being recognized with the 2023 AACR-CRI Lloyd J. Old Award in Cancer Immunology. Learn more: bit.ly/40qAhnB @CancerResearchView quoted post on X
Authored by Andrew G. Soerens et al, we show that #Tcells are capable of proliferating in response to iterative stimulation for over 10yrs! And produce enough progeny to occupy a volume 30,000x the Earth's volume! @Nature nature.com/articles/s4158…View quoted post on X
The first patient has been dosed with AB-1015 in a Phase 1, first-in-human clinical trial for patients with ovarian cancer that is resistant to platinum-based regimens. It is our first internally discovered T cell medicine to enter clinical development: shorturl.at/iwT03View quoted post on X
